PET/CT Indications
Aetna
FDG PET/CT Indications – Members benefit plan always supersedes the medical coverage
| Indication | Covered | Non-covered | Specific Criteria must be met |
Alzheimer’s/Demetia |
X | ||
Brain |
X | ||
Breast |
|||
Diagnosis |
X | ||
Initial Staging of axillary nodes/Staging of |
X | X | |
Cervical |
|||
Staging as adjunct to conventional imaging |
X | X | |
Other staging/Diagnosis/Restaging/Monitoring |
X | ||
Colorectal |
|||
Diagnosis/Monitoring |
X | ||
Staging/Restaging |
X | X | |
Esophagus |
|||
Diagnosis/Monitoring |
X | ||
Staging/Restaging |
X | X | |
Head & Neck (non-CNS/thyroid) |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Lymphoma |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Melanoma |
|||
Diagnosis/Monitoring |
X | ||
Staging/Restaging |
X | 1 PET/CT PER YEAR | |
Non-Small Cell Lung |
|||
Diagnosis/Monitoring |
X | ||
Staging/Restaging |
X | X | |
Ovarian |
X | ||
Pancreatic |
X | ||
Small Cell Lung |
X | ||
Soft Tissue Sarcoma |
X | ||
Solitary Pulmonary Nodule (characterization;<4cm) |
|||
Diagnosis |
X | ||
Staging/Restaging/Monitoring |
X | ||
Thyroid |
|||
Staging of follicular cell tumors |
X | X | |
Restaging of medullar cell tumors |
X | ||
Diagnosis, other staging & restaging, monitoring |
X | ||
Testicular |
X | ||
All other cancers not listed herein (all indications) |
X | ||
Refractory Seizures |
X | X | |
Monitoring = monitor response to treatment when a change in therapy is anticipated. General Frequency limitation: 90 days www.aetna.com |
|||
BCBS - Texas Christian University
FDG PET/CT Indications – Members benefit plan always supersedes the medical coverage
| Indication | Covered | Non-covered | Specific Criteria must be met |
Alzheimer’s/Dementia |
X | ||
Brain |
|||
Diagnosis, staging, restaging |
X | ||
Breast |
|||
Diagnosis |
X | ||
Initial Staging of axillary nodes/Staging of distant metastsis |
X | X | |
Monitoring/Restaging |
X | ||
Cervical |
|||
Staging as adjunct to conventional imaging/Other staging/ |
X | ||
Colorectal |
|||
Diagnosis/Monitoring |
X | ||
Staging/Restaging |
X | X | |
Esophagus |
|||
Staging/Restaging |
X | X | |
Diagnosis/Monitoring |
X | ||
Head & neck (non-CNS/thyroid) |
|||
Diagnosis |
X | X | |
Staging/Restaging/Monitoring |
X | ||
Lymphoma |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Melanoma |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | 1 PET/CT PER YEAR | |
Monitoring |
X | ||
Non-Small Cell Lung |
|||
Diagnosis/Monitoring |
X | ||
Staging/Restaging |
X | X | |
Ovarian |
X | ||
Pancreatic |
X | ||
Small Cell Lung |
X | ||
Soft Tissue Sarcoma |
X | ||
Solitary Pulmonary Nodule (characterization; <4cm) |
|||
Diagnosis |
X | X | |
Staging/Restaging/Monitoring |
X | ||
Thyroid |
|||
Staging of follicular cell tumors/Restaging of follicular cell |
X | ||
Testicular |
X | ||
All other cancers not listed herein (all indications) |
X | ||
Refractory Seizures |
X | X | |
Monitoring = monitor response to treatment when a change in therapy is anticipated. General Frequency limitation: 90 days RQI is required for PET/CT www.bcbstx.com |
|||
Cigna
FDG PET/CT Indications – Members benefit plan always supersedes the medical coverage
| Indication | Covered | Non-covered | Specific Criteria must be met |
Alzheimer’s/Dementia |
X | ||
Brain |
|||
Diagnosis, staging, restaging |
X | X | |
Breast |
|||
Diagnosis/Staging of distant metastasis/Restaging |
X | X | |
Initial staging of axillary nodes |
X | X | |
Monitoring |
X | ||
Cervical |
|||
Staging as adjunct to conventional imaging |
X | X | |
Other staging/Diagnosis/Restaging/Monitoring |
X | ||
Colorectal |
|||
Diagnosis/Staging/Restaging |
X | X | |
Monitoring |
X | ||
Esophagus |
|||
Diagnosis/Staging/Restaging |
X | X | |
Monitoring |
X | ||
Head & Neck (non-CNS/thyroid) |
|||
Diagnosis/Staging/Restaging |
X | X | |
Monitoring |
X | ||
Lymphoma |
|||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Melanoma |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | 1 PET/CT PER YEAR | |
Monitoring |
X | ||
Non-Small Cell Lung |
|||
Diagnosis/Staging/Restaging |
X | X | |
Monitoring |
X | ||
Ovarian |
X | ||
Pancreatic |
X | ||
Small Cell Lung |
X | ||
Soft Tissue Sarcoma |
|||
Solitary Pulmonary Nodule (characterization; <4cm) |
|||
Diagnosis |
X | X | |
Staging/Restaging/Monitoring |
X | ||
Thyroid |
|||
Staging of follicular cell tumors |
X | X | |
Restaging of follicular cell tumors |
X | X | |
Diagnosis, other staging & restaging |
X | ||
Testicular |
X | ||
All other cancers not listed herein (all indications) |
X | ||
Refractory Seizures |
X | X | |
Pre-cert/Auth required for some plan members (Medsolutions) General Frequency limitation: 90 days Monitoring = monitor reqponse to treatment when a change in therapy is anticipated. |
|||
Medicare, PacifiCare, Secure Horizons, Tricare, and other networks
FDG PET/CT Indications – Members benefit plan always supersedes the medical coverage
| Indication | Covered | Non-covered | Specific Criteria must be met |
Alzheimer’s Diseases vs. Fronto temporal Dementia |
|||
Diagnosis |
X | X | |
Brain Tumor |
|||
Diagnosis, staging, restaging |
X | ||
Breast |
|||
Diagnosis/Staging of distant metastasis/Restaging |
X | X | |
Diagnosis/Initial staging of axillary nodes |
X | ||
Monitoring |
X | ||
Cervical |
|||
Staging/Restaging as adjunct to conventional imaging |
X | X | |
Diagnosis/Monitoring |
X | ||
Colorectal |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Esophagus |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Head & Neck (non-CNS/thyroid) |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Lymphoma |
|||
Diagnosis |
X | ||
Staging/Restaging/Monitoring |
X | ||
Melanoma |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | 1 PET/CT PER YEAR | |
Monitoring |
X | ||
Non-Small Cell Lung |
|||
Diagnosis/Staging/Restaging |
X | X | |
Monitoring |
X | ||
Ovarian |
X | ||
Pancreatic |
X | ||
Small Cell Lung |
X | ||
Soft Tissue Sarcoma |
X | ||
Solitary Pulmonary Nodule (characterization; <4cm) |
|||
Diagnosis |
X | X | |
Staging/Restaging/Monitoring |
X | ||
Thyroid |
|||
Restaging of follicular cell tumors |
X | X | |
Diagnosis, other staging & restaging |
X | ||
Monitoring |
X | ||
Testicular |
X | ||
All other cancers not listed herein (all indications) |
X | ||
Refractory Seizures |
X | Pre-surgical evaluation only | |
General Frequency limitation: 90 days Monitoring = monitor response to treatment when a change in therapy is anticipated. Provider must register in order to log on to the site. |
|||
United Healthcare
FDG PET/CT Indications – Members benefit plan always supersedes the medical coverage
| Indication | Covered | Non-covered | Specific Criteria must be met |
Alzheimer’s/Dementia |
|||
Diagnosis |
X | X | |
Brain |
|||
Diagnosis, staging, restaging |
X | ||
Breast |
|||
Staging of distant metastasis/Restaging |
X | X | |
Diagnosis/Initial staging of axillary nodes |
X | ||
Cervical |
|||
Staging as adjunct to conventional imaging |
X | X | |
Other staging/Diagnosis/Restaging/Monitoring |
X | ||
Colorectal |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Esophagus |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Head & Neck (non-CNS/thyroid) |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | X | |
Monitoring |
X | ||
Lymphoma |
|||
Diagnosis |
X | ||
Staging/Restaging/Monitoring |
X | ||
Melanoma |
|||
Diagnosis |
X | ||
Staging/Restaging |
X | 1 PET/CT PER YEAR | |
Monitoring |
X | ||
Non-Small Cell Lung |
|||
Diagnosis/Staging/Restaging |
X | ||
Monitoring |
X | ||
Ovarian |
X | ||
Pancreatic |
X | ||
Small Cell Lung |
X | ||
Soft tissue Sarcoma |
X | ||
Solitary Pulmonary Nodule (characterization; <4cm) |
|||
Diagnosis |
X | X | |
Staging/Restaging/Monitoring |
X | ||
Thyroid |
|||
Staging of follicular cell tumors |
X | X | |
Restaging of follicular cell tumors |
X | X | |
Diagnosis, other staging & restaging |
|||
Monitoring |
X | ||
Testicular |
X | ||
All other cancers not listed herein (all indications) |
X | ||
Refractory Seizures |
X | X | |
Members benefits plan always superseded the medical coverage. Some plan members may require pre-cert/auth General Frequency limitation: 90 days |
|||